vs
ADMA BIOLOGICS, INC.（ADMA）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是RESOURCES CONNECTION, INC.的1.2倍（$139.2M vs $117.7M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -10.8%，领先46.2%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -19.2%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $15.6M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -11.8%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
ADMA vs RGP — 直观对比
营收规模更大
ADMA
是对方的1.2倍
$117.7M
营收增速更快
ADMA
高出37.5%
-19.2%
净利率更高
ADMA
高出46.2%
-10.8%
自由现金流更多
ADMA
多$19.0M
$15.6M
两年增速更快
ADMA
近两年复合增速
-11.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $117.7M |
| 净利润 | $49.4M | $-12.7M |
| 毛利率 | 63.8% | 37.1% |
| 营业利润率 | 45.1% | -10.3% |
| 净利率 | 35.5% | -10.8% |
| 营收同比 | 18.4% | -19.2% |
| 净利润同比 | -55.9% | 81.6% |
| 每股收益（稀释后） | $0.20 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARGP
| Q4 25 | $139.2M | $117.7M | ||
| Q3 25 | $134.2M | $120.2M | ||
| Q2 25 | $122.0M | $139.3M | ||
| Q1 25 | $114.8M | $129.4M | ||
| Q4 24 | $117.5M | $145.6M | ||
| Q3 24 | $119.8M | $136.9M | ||
| Q2 24 | $107.2M | $148.2M | ||
| Q1 24 | $81.9M | $151.3M |
净利润ADMARGP
| Q4 25 | $49.4M | $-12.7M | ||
| Q3 25 | $36.4M | $-2.4M | ||
| Q2 25 | $34.2M | $-73.3M | ||
| Q1 25 | $26.9M | $-44.1M | ||
| Q4 24 | $111.9M | $-68.7M | ||
| Q3 24 | $35.9M | $-5.7M | ||
| Q2 24 | $32.1M | $10.5M | ||
| Q1 24 | $17.8M | $2.5M |
毛利率ADMARGP
| Q4 25 | 63.8% | 37.1% | ||
| Q3 25 | 56.3% | 39.5% | ||
| Q2 25 | 55.1% | 40.2% | ||
| Q1 25 | 53.2% | 35.1% | ||
| Q4 24 | 53.9% | 38.5% | ||
| Q3 24 | 49.8% | 36.5% | ||
| Q2 24 | 53.6% | 40.2% | ||
| Q1 24 | 47.8% | 37.0% |
营业利润率ADMARGP
| Q4 25 | 45.1% | -10.3% | ||
| Q3 25 | 38.0% | -1.7% | ||
| Q2 25 | 35.1% | -47.0% | ||
| Q1 25 | 30.4% | -38.4% | ||
| Q4 24 | 32.6% | -52.7% | ||
| Q3 24 | 33.1% | -3.5% | ||
| Q2 24 | 36.6% | 7.6% | ||
| Q1 24 | 26.7% | 2.8% |
净利率ADMARGP
| Q4 25 | 35.5% | -10.8% | ||
| Q3 25 | 27.1% | -2.0% | ||
| Q2 25 | 28.1% | -52.6% | ||
| Q1 25 | 23.4% | -34.0% | ||
| Q4 24 | 95.2% | -47.2% | ||
| Q3 24 | 30.0% | -4.2% | ||
| Q2 24 | 29.9% | 7.1% | ||
| Q1 24 | 21.7% | 1.7% |
每股收益（稀释后）ADMARGP
| Q4 25 | $0.20 | $-0.38 | ||
| Q3 25 | $0.15 | $-0.07 | ||
| Q2 25 | $0.14 | $-2.21 | ||
| Q1 25 | $0.11 | $-1.34 | ||
| Q4 24 | $0.45 | $-2.08 | ||
| Q3 24 | $0.15 | $-0.17 | ||
| Q2 24 | $0.13 | $0.31 | ||
| Q1 24 | $0.08 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $89.8M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $194.6M |
| 总资产 | $624.2M | $289.3M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARGP
| Q4 25 | $87.6M | $89.8M | ||
| Q3 25 | $61.4M | $77.5M | ||
| Q2 25 | $90.3M | $86.1M | ||
| Q1 25 | $71.6M | $72.5M | ||
| Q4 24 | $103.1M | $78.2M | ||
| Q3 24 | $86.7M | $89.6M | ||
| Q2 24 | $88.2M | $108.9M | ||
| Q1 24 | $45.3M | $113.8M |
总债务ADMARGP
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARGP
| Q4 25 | $477.3M | $194.6M | ||
| Q3 25 | $431.2M | $206.4M | ||
| Q2 25 | $398.3M | $207.1M | ||
| Q1 25 | $373.4M | $277.8M | ||
| Q4 24 | $349.0M | $325.7M | ||
| Q3 24 | $231.9M | $407.2M | ||
| Q2 24 | $188.3M | $418.8M | ||
| Q1 24 | $153.7M | $414.9M |
总资产ADMARGP
| Q4 25 | $624.2M | $289.3M | ||
| Q3 25 | $568.7M | $287.2M | ||
| Q2 25 | $558.4M | $304.7M | ||
| Q1 25 | $510.6M | $375.6M | ||
| Q4 24 | $488.7M | $424.9M | ||
| Q3 24 | $390.6M | $512.9M | ||
| Q2 24 | $376.4M | $510.9M | ||
| Q1 24 | $350.9M | $523.2M |
负债/权益比ADMARGP
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $15.6M |
| 自由现金流率自由现金流/营收 | 24.8% | 13.2% |
| 资本支出强度资本支出/营收 | 0.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $24.3M |
8季度趋势，按日历期对齐
经营现金流ADMARGP
| Q4 25 | $35.6M | $15.9M | ||
| Q3 25 | $13.3M | $-7.8M | ||
| Q2 25 | $21.1M | $16.8M | ||
| Q1 25 | $-19.7M | $659.0K | ||
| Q4 24 | $50.2M | $1.8M | ||
| Q3 24 | $25.0M | $-309.0K | ||
| Q2 24 | $45.6M | $3.2M | ||
| Q1 24 | $-2.2M | $20.5M |
自由现金流ADMARGP
| Q4 25 | $34.6M | $15.6M | ||
| Q3 25 | $-1.1M | $-8.0M | ||
| Q2 25 | $18.7M | $16.5M | ||
| Q1 25 | $-24.4M | $238.0K | ||
| Q4 24 | $47.5M | $61.0K | ||
| Q3 24 | $24.0M | $-575.0K | ||
| Q2 24 | $43.6M | $3.0M | ||
| Q1 24 | $-4.6M | $20.4M |
自由现金流率ADMARGP
| Q4 25 | 24.8% | 13.2% | ||
| Q3 25 | -0.8% | -6.6% | ||
| Q2 25 | 15.3% | 11.8% | ||
| Q1 25 | -21.2% | 0.2% | ||
| Q4 24 | 40.4% | 0.0% | ||
| Q3 24 | 20.0% | -0.4% | ||
| Q2 24 | 40.7% | 2.1% | ||
| Q1 24 | -5.6% | 13.5% |
资本支出强度ADMARGP
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.3% | ||
| Q4 24 | 2.3% | 1.2% | ||
| Q3 24 | 0.9% | 0.2% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 2.9% | 0.1% |
现金转化率ADMARGP
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 0.30× | ||
| Q1 24 | -0.12× | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
